Browse News
Filter News
Found 200 articles
-
Monday’s announced buyout of Virginia-based Landos Biopharma adds a mid-stage, oral NLRX1 agonist for ulcerative colitis and Crohn’s disease to AbbVie’s growing portfolio.
-
AbbVie and Allergan Aesthetics to Present New Data at 2024 Annual AAD Meeting Showcasing Depth and Strength Across Dermatology and Aesthetics Portfolios
3/6/2024
AbbVie and Allergan Aesthetics, an AbbVie company, today announced they will present 29 abstracts, including three late-breaking presentations, during the 2024 American Academy of Dermatology (AAD) Annual Meeting, March 8-12, in San Diego, California.
-
AbbVie Unveils New Data from Robust Gastroenterology Portfolio at the 19th Congress of European Crohn's and Colitis Organisation (ECCO)
2/19/2024
AbbVie (NYSE: ABBV) announced that 17 AbbVie-sponsored abstracts, including new data from its inflammatory bowel disease (IBD) portfolio, have been accepted for presentation at the 19th Congress of European Crohn's and Colitis Organisation (ECCO) taking place in Stockholm, Sweden from February 21-24.
-
While AbbVie beat revenue expectations in the fourth quarter of 2023, the company reported Friday that its overall sales last year declined as it faced biosimilar competition for its blockbuster Humira.
-
AbbVie Reports Full-Year and Fourth-Quarter 2023 Financial Results
2/2/2024
AbbVie (NYSE:ABBV) announced financial results for the fourth quarter and full year ended December 31, 2023.
-
Enthera Pharmaceuticals Appoints Lisa M. Olson as CEO and Announces Clinical Trial Progress with Ent001
1/23/2024
Enthera Pharmaceuticals, a clinical-stage biotech company developing first-in-class antibody therapeutics targeting the Insulin Growth Factor Binding Protein family for selected inflammatory diseases, announced the appointment of Lisa M. Olson, Ph.D., as the company’s Chief Executive Officer.
-
ABIONYX Pharma appoints Rob Scott, MD, as Chief Medical Officer and Head of R&D
1/8/2024
ABIONYX Pharma is pleased to announce the appointment of Dr. Rob Scott as Chief Medical Officer and Head of R&D with immediate effect.
-
The pharmacy benefit management subsidiary of CVS Health is favoring Humira’s biosimilars for its major formularies, with AbbVie’s branded product to be nixed on April 1, 2024.
-
The market size for biologic oncology therapies will reach $786 billion by 2029, far outstripping small molecules, a GlobalData report predicts.
-
Pediatric Drugs Market Size to Garner Around USD 363.86 Billion by 2032
11/8/2023
The global pediatric drugs market size is predicted to garner around USD 363.86 billion by 2032 and is expanding at a CAGR of 12.2% over the forecast period 2023 to 2032.
-
AbbVie Reports Third-Quarter 2023 Financial Results
10/27/2023
AbbVie (NYSE:ABBV) announced financial results for the third quarter ended September 30, 2023.
-
Lupus Therapeutics Partners with AbbVie on Clinical Trial Recruitment Efforts in SLE Through LuCIN Lupus Clinical Trial Network
10/24/2023
Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, announces a partnership with AbbVie Inc. for the Phase 3 clinical program of upadacitinib (RINVOQ ® ) in individuals living with systemic lupus erythematosus (SLE).
-
AbbVie Announces Upadacitinib (RINVOQ®) Met the Primary Endpoint in Phase 2 Clinical Trial of Vitiligo as Program Advances to Phase 3
10/12/2023
AbbVie announced that its Phase 2b study evaluating upadacitinib in adults with non-segmental vitiligo met the primary endpoint of percent change from baseline in the Facial Vitiligo Area Scoring Index at week 24 with the 11 mg and 22 mg doses versus placebo.
-
AbbVie Presents Long-Term Data Further Supporting the Efficacy and Safety Profile of RINVOQ (upadacitinib) in Adults and Adolescents with Moderate to Severe Atopic Dermatitis
10/11/2023
AbbVie (NYSE: ABBV) today announced new data analyses from the Measure Up 1, Measure Up 2 and AD Up Phase 3 studies that further demonstrated the long-term efficacy and safety profile of RINVOQ® (upadacitinib) among adults and adolescents 12 years and older with moderate to severe atopic dermatitis through 140 weeks.
-
AbbVie Showcases Breadth and Depth of Research in Crohn's Disease and Ulcerative Colitis at UEG Week 2023
10/10/2023
AbbVie (NYSE: ABBV) will share new data from its robust gastroenterology portfolio at the United European Gastroenterology (UEG) Week 2023 Congress taking place in Copenhagen, Denmark from October 14-17.
-
Odyssey Therapeutics Appoints Jeremy Sokolove, MD as Chief Medical Officer
10/4/2023
Odyssey Therapeutics, Inc. today announced the appointment of Jeremy Sokolove, M.D., as chief medical officer.
-
As biosimilars and next-generation treatments for Crohn’s disease enter the market, AbbVie will be knocked from its place of longtime dominance, contends data and analytics firm GlobalData.
-
AbbVie Reports Second-Quarter 2023 Financial Results
7/27/2023
AbbVie (NYSE:ABBV) announced financial results for the second quarter ended June 30, 2023.
-
AbbVie Advances Immunology Pipeline with First Patient Dosed in Global Phase 3 Trial of Upadacitinib (RINVOQ®) in Hidradenitis Suppurativa
7/24/2023
AbbVie (NYSE: ABBV) today announced that the first patient has been dosed in the Phase 3 Step-Up HS study evaluating upadacitinib (RINVOQ®) in adults and adolescents with moderate to severe hidradenitis suppurativa (HS) who have failed anti-tumor necrosis factor (TNF) therapy and/or one approved non-anti-TNF inhibitor therapy for HS.1
-
Pfizer’s Litfulo Poised to Follow Similar Trajectory as Eli Lilly/Incyte’s Olumiant for the Treatment of Severe Alopecia Areata
7/11/2023
In June 2022, Eli Lilly and Incyte’s Olumiant became the first and only approved advanced systemic treatment for adults with severe alopecia areata.